{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"PFS was calculated from the first dose of study drug to the first documentation of disease progression, death regardless of cause, or change in therapy due to disease progression, whichever occurred first. If disease progression did not occur by the end of treatment, patients were evaluated every 3 months until progression with physical examination, laboratory studies, and conventional computed tomographic imaging, up to a maximum of 2 years. The Kaplan-Meier product-limit method will be used to estimate progression-free survival in the presence of censoring.","groups":[{"description":"* Rituximab 375 mg/m2 IV day1\n* Cladribine 4 mg/m2 IV over 2 hours days 1-5\n* Bortezomib 1.3 mg/m2 IV days 1 and 4\n* Repeat every 28 days for a maximum of 6 cycles\n\nrituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.\n\nbortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.\n\ncladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.","id":"OG000","title":"VCR (Velcade, Cladribine and Rituximab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression-free Survival at 2 Years","type":"PRIMARY","unitOfMeasure":"Participants"}